IQVIA , a global leader in clinical research services and healthcare intelligence, has announced a strategic collaboration with SCRI Development Innovations, the contract research organization (CRO) arm of Sarah Cannon Research Institute. This alliance aims to transform the conduct of oncology trials for biopharmaceutical companies around the world.
The partnership brings together IQVIA’s global capabilities in data, technology, and analytics—managing one in five oncology trials in the U.S.—with SCRI Development Innovations’ deep expertise in community-based oncology research. The collaboration will streamline clinical trial operations, eliminate common logistical and operational challenges, and significantly accelerate the development and delivery of advanced cancer therapies to patients.
A key feature of this collaboration is the integration of SCRI’s Accelero operational model, which enhances trial activation speed and patient recruitment at SCRI sites across the U.S. Accelero allows for seamless data integration from electronic health records (EHR) to electronic data capture (EDC) systems, improving the efficiency and accuracy of clinical trial data collection. When combined with IQVIA’s global scale and technological infrastructure, this model offers sponsors a comprehensive and streamlined solution for trial execution.
“We are thrilled to collaborate with SCRI Development Innovations,” said Richard Staub, President of Research & Development Solutions at IQVIA. “This partnership exemplifies our shared commitment to innovation and efficiency. By unifying our strengths, we can reduce the complexity of multi-vendor environments and accelerate the development of novel cancer treatments that improve patient outcomes.”
Dee Anna Smith, CEO of Sarah Cannon Research Institute, echoed the enthusiasm: “Through our Accelero model, we are easing the operational burden on research sites while improving enrollment and data delivery. By aligning with IQVIA, we can extend our capabilities globally and deliver a seamless experience for trial sponsors and patients alike.”
This collaboration represents a pivotal advancement in oncology trial delivery worldwide. Attendees of the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago, Illinois, can learn more about the partnership by visiting IQVIA at Booth 14103 or SCRI at Booth 27022.